Molecular biology of pancreatic cancer

Clinical and Translational Oncology

Volumn 10, Issue 9, 2008, Pages 530-537

  Belda Iniesta, Cristóbal ^a   De Cáceres, Inmaculada Ibáñez ^a,b,c   Barriuso, Jorge ^a   De Castro Carpeño, Javier ^a   Barón, Manuel González ^a,b   Feliú, Jaime ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c CSIC   (Spain)

Author keywords

Cyclins; EGFr; K ras; Pancreatic cancer; STAT3; TGF

Indexed keywords

GENETIC PREDISPOSITION; GENETICS; HUMAN; MOLECULAR BIOLOGY; PANCREAS TUMOR; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR BIOLOGY; PANCREATIC NEOPLASMS;

EID: 56149100868     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0247-6     Document Type: Article

References (63)

1. Izeradjene K, Combs C, Best M et al (2007) Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11:229-243
2. Hruban RH, Goggins M, Parsons J et al (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972
3. Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-450
4. Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483
5. Bardeesy N, Aguirre AJ, Chu GC et al (2006) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103:5947-5952
6. Aguirre J, Bardeesy N, Sinha M et al (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112-3126
7. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science DOI10.1126/Science. 1164368
8. Quinlan MP, Quatela SE, Philips MR et al (2008) Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol 28:2659-2674
9. Park SW, Davison JM, Rhee J et al (2008) Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology 134:2080-2090
10. Pickles M, Leask A (2007) Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK. J Cell Commun Signal 1:85-90
11. Aikawa T, Gunn J, Spong SM et al (2006) Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 5:1108-1116
12. Ji Z, Mei FC, Xie J et al (2007) Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 282:14048-14055
13. Skalicky DA, Kench JG, Segara D et al (2006) Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 15:1941-1947
14. Biankin AV, Biankin SA, Kench JG et al (2002) Cyclin D regulates FGFR-1 isoforms IIIc and IIIb (isoform IIIc enhances and FGFR1-IIIb inhibits pancreatic cancer cell growth. Gut 50:861-868
15. Chen G, Wang J, Liu Z et al (2008) Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1. Pancreas 37:159-164
16. Tiemann K, Heitling U, Kosmahl M et al (2007) Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pa-thol 20:955-960
17. Ghiorzo P, Pastorino L, Bonelli L et al (2004) INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 15:70-78
18. Moskaluk CA, Hruban H, Lietman A et al (1998) Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Hum Mutat 12:70
19. Redston MS, Caldas C, Seymour AB et al (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54: 3025-3033
20. Yan W, Liu G, Scoumanne A et al (2008) Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res 68:6789-6796
21. Miyasaka Y, Nagai E, Yamaguchi H et al (2007) The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 13:4371-4377
22. Logsdon CD, Simeone DM, Binkley C et al (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649-2657
23. Guweidhi A, Kleeff J, Giese N et al (2004) Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 25:1575-1585
24. Zawel L, Dai JL, Buckhaults P et al (1998) Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1:611-617
25. Peng B, Fleming JB, Breslin T et al (2002) Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 8:3628-3638
26. Zhao S, Venkatasubbarao K, Lazor JW et al (2008) Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68:4221-4228
27. Ueda S, Ogata S, Tsuda H et al (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29: e1-8
28. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
29. Siveke JT, Einwächter H, Sipos B et al (2007) Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12: 266-279
30. Schreiner B, Greten FR, Baur DM et al (2003) Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes with two independently amplified gene loci. Oncogene 22:6802-6809
31. Tzeng CW, Frolov A, Frolova N et al (2007) Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141:464-469
32. Tzeng CW, Frolov A, Frolova N et al (2007) EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res 143: 20-26
33. Holzmann K, Kohlhammer H, Schwaenen C et al (2004) Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res 64: 4428-4433
34. Pino MS, Shrader M, Baker CH et al (2006) Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 66:3802-3812
35. Kwak EL, Jankowski J, Thayer SP et al (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287
36. Hurtado M, Lozano JJ, Castellanos E et al (2007) Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. Gut 56:1266-1274
37. Billadeau DD, Chatterjee S, Bramati P et al (2006) Characterization of the CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Cancer 37:110-119
38. Tan X, Egami H, Abe M et al (2005) Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEKERK signal transduction pathway. J Clin Pathol 58:1242-1248
39. Takai E, Tan X, Tamori Y et al (2005) Correlation of translocation of tight junction protein Zonula occludens-1 and activation of epidermal growth factor receptor in the regulation of invasion of pancreatic cancer cells. Int J Oncol 27: 645-651
40. Jimeno A, Tan AC, Coffa J et al (2008) Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 68:2841-2849
41. Sloss CM, Wang F, Liu R et al (2008) Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res 14:5116-5123
42. DeArmond D, Brattain MG, Jessup JM et al (2003) Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 22:7781-7795
43. Algül H, Wagner M, Lesina M et al (2007) Overexpression of ErbB2 in the exocrine pancreas induces an inflammatory response but not increased proliferation. Int J Cancer 121:1410-1416
44. Buck E, Eyzaguirre A, Haley JD et al (2006) Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5:2051-2059
45. Büchler P, Reber HA, Lavey RS et al (2004) Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 120:295-303
46. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893
47. Seo Y, Baba H, Fukuda T et al (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239-2245
48. Büchler P, Reber HA, Büchler MW et al (2002) VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 236:738-749
49. Fukahi K, Fukasawa M, Neufeld G et al (2004) Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res 10: 581-590
50. Saif MW (2006) Anti-angiogenesis therapy in pancreatic carcinoma. JOP 7:163-173
51. McCarty MF, Somcio RJ, Stoeltzing O et al (2007) Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 117: 2114-2122
52. Shen J, Vil MD, Zhang H et al (2007) An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357:1142-1147
53. Esposito I, Menicagli M, Funel N et al (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57:630-636
54. Teraoka H, Sawada T, Nishihara T et al (2001) Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 85:612-617
55. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
56. Schönleben F, Allendorf JD, Qiu W et al (2008) Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas 36:168-172
57. Schönleben F, Qiu W, Remotti HE et al (2008) PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg 393:289-296
58. Haigis KM, Kendall KR, Wang Y et al (2008) Differential effects of oncogenic K-Ras and NRas on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600-608
59. Mijatovic T, Gailly P, Mathieu V et al (2007) Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell Oncol 29:315-326
60. Reichert M, Saur D, Hamacher R et al (2007) Fbox protein SKP2, an oncogene up-regulated in PDAC, is transcriptionally regulated by the PI3K/AKT1 pathway in PDAC cells. Cancer Res 67:4149-4156
61. Yamada N, Nishida Y, Tsutsumida H et al (2008) MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 68:2708-2716
62. Yamada N, Hamada T, Goto M et al (2006) MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 119:1850-1857
63. Fauquette V, Aubert S, Groux-Degroote S et al (2007) AP-2alpha is an important in vivo negative regulator of MUC4 expression in human pancreatic tissue and that AP-2alpha may play a tumoursuppressive role in pancreatic DAC. Carcinogenesis 28:2305-2312